Combining salicylate and enalapril in patients with coronary artery disease and heart failure


Abstract

Objective—To study the effects of adding a salicylate to the angiotensin converting enzyme inhibitor enalapril in patients with heart failure due to coronary artery disease.

Design—Double blind, crossover study for three days in hospital followed by an extended similar study outside hospital over two months of once daily enalapril plus salicylate and enalapril plus placebo.

Setting—Tertiary referral centre.

Patients—20 patients with heart failure due to myocardial infarction (New York Heart Association class II or III) and an ejection fraction less than 0.40. Twelve patients completed the two parts of the study.

Main outcome measures—Blood pressure, plasma converting enzyme activity; plasma angiotensin II and noradrenaline concentrations; excretion of metabolites of renal and systemic prostanoids.

Results—The unloading effect of first and second dose of enalapril in the morning lasted only during the day; in the extended study it lasted 24 hours because of the drug’s accumulation. Converting enzyme inhibitors attenuate the breakdown of bradykinin and therefore enhance prostaglandin E2 synthesis mediated by bradykinin. Evidence was found of such a prostaglandin E2 mediated contribution to ventricular unloading by enalapril, which was blocked by salicylate. The contribution, however, was small and variable, and salicylate addition had on average no significant de-unloading effect during the day. Unloading was abolished in only three of the 20 patients in the short term study and in one of the 12 in the extended study. At night, when other effects of enalapril on blood pressure had waned and the bradykinin induced effect persisted, salicylate significantly reduced the remaining small unloading effect. No effect was seen of salicylate addition on reversal of remodelling. Enalapril reduced angiotensin II induced synthesis of systemic and renal prostaglandin I2 and thromboxane A2, initially only during the day, but later also at night. It thereby masked suppression of thromboxane A2 synthesis by salicylate, which is the effect to which reinfarct prevention by salicylate is attributed.

Conclusion—The risk is low that salicylate will substantially reduce the benefit of enalapril in patients with heart failure by de-unloading the ventricle. Like other effects induced by bradykinin significant de-unloading occurs in only a minority of the patients. In the presence of enalapril, however, salicylate will probably not be as effective as expected in reducing reinfarction risk, because enalapril already reduces thromboxane A2 synthesis effectively in patients with heart failure and no further reduction by salicylate was found.

Keywords: angiotensin converting enzyme inhibition; prostaglandin; heart failure; prevention of reinfarction

Treatment with an angiotensin converting enzyme inhibitor is indicated in patients with heart failure who have an ejection fraction of less than 0.40, irrespective of their symptoms. Enalapril was the first converting enzyme inhibitor to be shown to reduce mortality and delay progression from mild to severe congestive failure.1 In patients who survived a myocardial infarction, treatment with a salicylate once daily and in a low dose reduced the reinfarction rate and mortality.2 As converting enzyme inhibitors act differently from salicylates, it seems reasonable to expect that patients who survive an infarction and have a low ejection fraction will benefit more from taking the two drugs than from taking only one.

The beneficial action of converting enzyme inhibitors in heart failure is attributed to unloading the ventricle without undue sympathetic stimulation of the heart and to reversing, or at least retarding, the progression of dilatation and hypertrophy. The unloading effect of converting enzyme inhibitors is considered to be partly due to an increased production of vasodilating prostaglandins.3–6 This production might therefore be severely reduced if converting enzyme inhibitors are combined with non-steroidal anti-inflammatory drugs.7 Evidence in favour of the existence of such a “de-unloading” effect in patients with heart failure was reported recently—adding salicylate to enalapril raised arterial and left ventricular filling pressure in patients with heart failure.8 It is by no means clear, however, to what extent ventricular unloading by converting enzyme inhibitors is attributable to increased prostanoid production and, if so, to what extent a low dose of a salicylate will reduce the effect.
The renin-angiotensin system also affects the synthesis of prostanooids in the systemic and renal circulation. Angiotensin converting enzyme is identical to kininase II, which breaks down bradykinin. Therefore, converting enzyme inhibitors increase endogenous bradykinin concentrations, increasing the release of vasodilating prostaglandin I₂ and E₁ into the systemic circulation. Such stimulation of prostaglandin synthesis contributed to the antihypertensive and unloading action of converting enzyme inhibitors. Angiotensin II activates production of the vasodilating prostanooids prostaglandin I₂ and prostaglandin E₁ in the kidney, which is the mechanism underlying activation of renal prostaglandin synthesis by diuretics. Converting enzyme inhibitors are therefore expected to reduce rather than enhance renal prostanooid synthesis. Occasionally, however, renal prostanooid synthesis has been stimulated (albeit indirectly) rather than suppressed by converting enzyme inhibitors. This is because converting enzyme inhibition potentiates the conversion of angiotensin I into angiotensin (1–7), which like angiotensin II stimulates the synthesis of vasodilating renal prostanooids. Angiotensin II induced contractions of isolated blood vessels are attenuated by indomethacin and by blockade of thromboxane receptors, suggesting the existence of a thromboxane mediated amplification of angiotensin II induced vasoconstriction. Converting enzyme inhibitors and salicylate can both be expected to reduce such a thromboxane mediated effect.

In view of the conflicting effects that converting enzyme inhibitors may have on systemic and renal prostanooid synthesis, the de-unloading effect of salicylate in patients treated with a converting enzyme inhibitor is probably less consistent than suggested previously. It may depend on dosage and relative timing of the two drugs, and it may vary from patient to patient. Therefore, to interpret results of studies of the addition of a non-steroidal anti-inflammatory drug to a converting enzyme inhibitor, the effects of drug treatment on haemodynamic parameters and on renal and systemic prostanooid synthesis must be measured.

To obtain such data we studied the effects of a single dose of salicylate on the day after starting enalapril in 20 patients with coronary artery disease and severe cardiac failure. To find out whether salicylate addition exerted any influence on the long term effects of the converting enzyme inhibitor on haemodynamic load and geometry of the left ventricle, we extended the study for four weeks.

Patients and methods

Participants in the study were recruited among patients admitted to the hospital for clinical evaluation of cardiac pump function and for instigation of medical treatment for heart failure. They were asked to participate if they fulfilled the entrance criteria and had none of the exclusion criteria. Twenty patients (18 men, two women) entered the study; their ages ranged from 23 to 70 years (mean 60). They all had coronary artery disease and cardiac failure (New York Heart Association class II or III) as a result of one, or occasionally several, myocardial infarctions. Left ventricular ejection fractions were less than 0.40 (mean 0.25). Exclusion criteria were overt decompensation, unstable angina, recent infarction, hyponatremia, albuminuria, a serum creatinine concentration above 150 μmol/l, renal artery stenosis, peptic ulcer or congenital heart disease, and the regular use of non-steroidal anti-inflammatory drugs, corticosteroids, or immunosuppressive drugs. One patient was withdrawn because of severe hyponatremia after the first dose of enalapril.

The study lasted three days, during which the patients remained in hospital. Immediately thereafter, they all entered into an eight weeks extension of the study outside hospital, for which they were scheduled to return twice to the outpatient clinic for extensive evaluation. Participation in the extension of the study was terminated if there were major complications, such as myocardial infarction, unstable angina, or decompensation, or if the patient's physician found it necessary to substantially change the dose of either the diuretic or the converting enzyme inhibitor. Eight patients were withdrawn: five because of major changes in drug treatment and three for other reasons. One was withdrawn because of unstable angina requiring an acute bypass operation, the second because of the detection of a malignant tumour, and the last at his own request. Twelve patients thus completed the extended study. Before entry all patients gave their informed consent. The study was approved by the medical ethics committee of the hospital.

Study design

The study was designed as a double blind, crossover trial comparing salicylate with placebo, both added to a converting enzyme inhibitor. The order of placebo and active treatment was not randomised and all patients first received a placebo followed by active treatment the next day. However, neither patients nor the medical and nursing staff involved were informed about the order in which the agents were given. All blood and urine samples were analysed by laboratory staff blinded to patients' identity and the order of sampling. Patients remained in hospital for at least three days, the first day taking no study medication to obtain baseline values, the second day taking enalapril and placebo, and the third day taking enalapril plus salicylate.

During the extension of the study, patients were also unaware that first a placebo was added for four weeks, followed by salicylate for another four weeks. The house staff involved in measuring blood pressure and taking samples were also not informed. The investigator who performed the echographic studies had to know the order of treatment, however.
DRUG TREATMENT
Ten patients were taking a converting enzyme inhibitor before admission. This treatment
was stopped at least two days before the study. All other treatments were continued.
Every patient used phenprocoumon as an anticoagulant. Thirteen patients took
frusemide, three digoxin, four a long acting nitrate, four a calcium antagonist, and two
patients an antiarrhythmic drug. To obtain baseline values no converting enzyme
inhibitor was given on the first day of the study. From the second day onwards,
enalapril was given in a dose that was kept fixed for the duration of the study; 5 mg once
daily to five patients and 10 mg once daily to 15, the dose depending on the patients’ renal
function. A placebo was added to the first
dose of enalapril, the next day 300 mg of car-
baspirin calcium, a complex of urea and cal-
cium acetylsalicylate, was added, which
represents 250 mg aspirin. The same
dose regimen was used in the extension of the
study.

MEASUREMENTS
Echocardiography was performed at the
beginning of the study and after four and
eight weeks. A Vingmed CFM-750 echocar-
diograph (Trondheim, Norway) was used, linked
to an Apple-Macintos computer for
data analysis. Exercise tests were performed
on a bicycle ergometer equipped with an
Oxycon V system for measuring oxygen
consumption (Mijnhardt, Bunnik, The
Netherlands). Blood pressure was measured
before and five and 24 hours after treatment
with an automatic device that took 10 read-
ings within 30 minutes (Accutor, Datascop,
Montvale, NJ, USA). From the readings of
systolic and diastolic pressures, a mean pres-
sure was calculated by adding one third of the
difference to the value of the diastolic pres-
sure. All values given are means of 10 consec-
tutive mean pressures. Immediately after the
pressure recordings, blood samples were
taken to determine plasma concentrations of
angiotensin II, noradrenaline, sodium, potas-
sium, and creatinine; plasma activities of
angiotensin converting enzyme; and plasma
osmolality.

Blood samples were taken when the
patients were supine and had been at rest for
at least two hours. Samples for angiotensin II
measurements, collected in tubes containing
disodium edetate and phenanthroline, were
put on ice immediately and centrifuged as
soon as possible in a precooled centrifuge; the
plasma was subsequently stored at -70°C. Angiotensin II was purified using solid phase extraction with SEP-Pak C-18 cartridges
(Waters Associates, Milford, MA, USA); it was
measured by radioimmunoassay using a
polyclonal antibody (Ang II-AS No 923) pro-
duced by Hoffmann-LaRoche (Basle,
Switzerland). Plasma angiotensin converting
enzyme activity was measured by a colorimet-
ric method with a test kit (Fuji Rebio, Tokyo,
Japan). Noradrenaline was assayed by an
electrochemical detection method after purifi-
cation with a high pressure liquid chromato-
graphy technique. Urine was collected from
2300 to 0800 and, during the first three days in
hospital, also from 0900 to 1300.

Data were collected after four and eight
weeks during a visit to the outpatient clinic,
where patients brought their urine collected
from 2300 to 0800. From urinary concentra-
tions of sodium, creatinine, and prostanoid
metabolites, the sodium excretion, free water
production, and creatinine clearance were cal-
culated. Male patients were asked to defer ejaculation. A sample of the urine collected
(50 ml) was centrifuged in a precooled cen-
trifuge and subsequently stored at -70°C
until further analysis. Concentrations of the
prostanoid metabolites thromboxane B2 and
6-ketoprostaglandin F1α, and of its diol equiv-
alent were measured using high pressure liq-
id chromatography and radioimmunoasay.
The techniques used to measure prostanoid
metabolites in the urine have been described
elsewhere.7,18 Excretion of thromboxane B2
and of 6-ketoprostaglandin F1α predominantly
reflects the renal biosynthesis of thromboxane
A2 and prostaglandin I2, respectively, while
the excretion of the dinor metabolites reflects
systemic synthesis.19

STATISTICAL ANALYSIS
Results are reported as means and standard
deviations. Results were compared using
analysis of variance, t tests with Bonferroni
correction, and paired t tests when appropri-
ate. Differences were considered to be signifi-
cant at P < 0.05.

Results
RENIN-ANGIOTENSIN SYSTEM
Without treatment plasma converting enzyme
activity was high in all patients (39.3 (17.8)
U/l) and remained remarkably constant dur-
ing the day, the difference between values in
the morning and afternoon being less than
0.3% (figure 1). Five hours after the first dose
of enalapril, plasma converting enzyme activity
had dropped to 9.1 (7.6) U/l. The next
morning before treatment it had risen to 16.1
(12.3) U/l. Five hours after the second dose it
was 8.2 (9.1) U/l, and it subsequently
increased to 18.8 (13.0) U/l the next morning.
Enalapril in a rather low dose and given once
daily reduced plasma converting enzyme
activity to 25% of pretreatment values around
noon and to 50% early the next morning.

Before treatment plasma angiotensin II
concentrations were high in almost all patients
and, unlike plasma converting enzyme activ-
ities, they showed a circadian variation. Mean
baseline values increased from 47.0 (31.7)
pg/ml early in the morning to 64.5 (48.0)
pg/ml in the afternoon (P < 0.01). Despite
the steep fall of plasma converting enzyme
activity after the first dose of enalapril, the
mean angiotensin II concentration measured
at noon (five hours after taking enalapril) was
only slightly and insignificantly lower than the
day before (58.7 (46.6) pg/ml). Two groups
of patients (I and II) could be distinguished
on the basis of their plasma angiotensin II concentration after the first dose of enalapril. Angiotensin II concentrations in the nine patients in group I did not fall. Values were on average up to 53% higher than those the day before; the mean value at noon increased from 49·0 (27·9) pmol/l to 75·1 (52·6) pmol/l (P < 0·03). Group II comprised 11 patients; their midday plasma angiotensin II concentrations were lower than the day before and the mean value for this group dropped from 82·6 (58·0) pmol/l to 47·7 (39·5) pmol/l (P < 0·01). Groups I and II did not differ with respect to dose of enalapril or previous use of a converting enzyme inhibitor. Blood pressures in the two groups did not differ either, but pretreatment angiotensin II concentrations in group II were 1·7 times higher than those in group I (NS) and corresponding noradrenaline concentrations were as much as twice as high (P < 0·05). The plasma converting enzyme activity before treatment was similar in both groups, but after treatment patients in group I had a plasma converting enzyme activity more than twice as high as that of patients in group II (P < 0·05). This indicated that although the renin-angiotensin system and sympathetic nervous system of patients in group II was initially more strongly activated, their converting enzyme activity was more effectively inhibited.

On the second day of treatment four patients still had plasma angiotensin II concentrations at noon that were slightly above their respective pretreatment values, but the mean values in groups I and II were no longer significantly different and the mean value for the whole group fell to 59% of its pretreatment mean value (37·9 (24·4) pmol/l).

**BLOOD PRESSURE**

Average mean blood pressures in the morning and at noon were initially 84·2 (11·0) mm Hg and 85·2 (10·6) mm Hg (figure 1). After the first dose of enalapril mean blood pressure fell to 72·2 (9·4) mm Hg at noon, which was 13 mm Hg lower than on the day before; it subsequently increased to 79·2 (10·6) mm Hg early next morning. After the second dose of enalapril, combined with salicylate, pressure fell to 70·5 (10·7) mm Hg at noon, which was not significantly different from the pressure on the first day of treatment after enalapril alone. Thus, at first sight, salicylate did not seem to reverse the unloading effect of enalapril. In three patients the unloading effect of enalapril was completely abolished and their blood pressure was on average almost 15 mm Hg higher than the day before. Blood pressure after enalapril and salicylate was on average 2·8 mm Hg higher than after enalapril and placebo in another seven patients (NS). Thus, salicylate reversed the unloading effect of enalapril in three out of 20 cases and may have attenuated the effect in a few others.

After salicylate blood pressure increased overnight to 83·3 (9·9) mm Hg early in the morning, which was significantly higher than the corresponding value after enalapril without salicylate (P < 0·05). During the night, when the effect of the enalapril had waned, salicylate thus came close to abolishing the remaining unloading effect of enalapril if it was still present.

**RENAL FUNCTION**

Creatinine clearance before treatment showed circadian variation (114 (72) ml/min/1·73m² in the morning v 59 (29) ml/min/1·73m² during the night). Daytime clearance fell to 80 (63) ml/min/1·73m² after enalapril and placebo and to 79 (60) ml/min/1·73m² after enalapril and salicylate. Creatinine clearances measured during the night were unaffected, being 59 (25) ml/min/1·73m² after the first day of treatment and 57 (34) ml/min/1·73m² after the second. All patients while in hospital...
Prostanoids

Daytime excretion of the dinor metabolites of systemically produced prostanoids was about twice as high as that during the night (figure 2). The excretion of dinor-6-ketoprostaglandin \( F_{1\alpha} \) was 27·3 (23·9) ng/h during the morning and 12·3 (6·6) ng/h at night; corresponding values for dinor-thromboxane \( B_2 \) were 34·9 (40·0) ng/h and 17·2 (11·8) ng/h. The ratio of prostaglandin \( F_{1\alpha} \) to thromboxane \( B_2 \) concentration were 0·78 and 0·71, which is below the normal value of about 1. Morning excretion of dinor-6-ketoprostaglandin \( F_{1\alpha} \) and dinor-thromboxane \( B_2 \) dropped significantly after the first dose of enalapril to 18·6 (21·3) ng/h and 20·8 (17·2) ng/h, respectively; their ratio thus increased to 0·89. The figures were not significantly influenced by adding salicylate (15·7 (12·6) and 25·6 (28·9) nmol/h). In contrast, the night time excretion of dinor-thromboxane \( B_2 \), which was not influenced by the converting enzyme inhibitor, dropped sharply after addition of the salicylate from 19·9 (15·4) ng/h to 7·3 (13·2) ng/h; excretion of dinor-6-ketoprostaglandin \( F_{1\alpha} \) was not changed. As a result, the ratio of prostaglandin \( F_{1\alpha} \) to thromboxane \( B_2 \) concentration increased to 1·26, which is distinctly higher than normal.

The effects of the converting enzyme inhibitor and the salicylate on the excretion of the renal prostanoids were quite similar to those on the excretion of systemic prostanoids. Renal prostanoid excretion showed circadian variation like that of the systemic equivalents, but the ratio of prostaglandin \( F_{1\alpha} \) to thromboxane \( B_2 \) concentration was 1·9 in the morning and 2·0 at night, which is about twice the normal value. Excretion of 6-ketoprostaglandin \( F_{1\alpha} \) was 18·3 (16·4) ng/h in the morning and 8·6 (6·3) ng/h during the night. Corresponding values for thromboxane \( B_2 \) were 9·5 (10·4) ng/h and 4·3 (2·8) ng/h respectively. As for the systemic prostanoids, the converting enzyme inhibitor had no effect on excretion during the night, but it reduced both 6-ketoprostaglandin \( F_{1\alpha} \) and thromboxane \( B_2 \) excretion during the day to 11·5 (8·6) ng/h and 6·3 (4·7) ng/h, respectively. The addition of salicylate had no additional effect and left the daytime excretions at 11·5 (9·3) ng/h and 4·9 (4·1) ng/h. Similar to what was found for the systemic prostanoids, salicylate had no effect on daytime excretion of prostanoids, while during the night only the excretion of thromboxane \( B_2 \) was reduced, from 4·2 (2·0) to 2·4 (2·2) ng/h. The night time excretion of 6-ketoprostaglandin \( F_{1\alpha} \) was 7·3 (3·7) ng/h after enalapril and placebo and 6·6 (4·4) ng/h after enalapril and salicylate (NS).
EXTENDED STUDY

Converting enzyme inhibitor and salicylate showed a consistent effect in the 12 patients who completed the extended study. Blood pressure in the early afternoon fell from 86-8 (10-3) mm Hg to 76-7 (9-7) mm Hg after four weeks and to 75-4 (10-5) mm Hg after eight weeks (figure 3). This means that, as in the short term study, there was on average no reversal of unloading. Unloading was, however, completely abolished in one patient and was partly, but not significantly, reversed in three others.

Plasma converting enzyme activity fell from 39-6 (23-0) pmol/l at baseline to 8-3 (5-5) pmol/l and 6-0 (3-4) pmol/l after four and eight weeks respectively (figure 3). Plasma angiotensin II and noradrenaline concentrations, which showed either inconsistent changes or none at all after the first dose of enalapril, were both lowered after eight weeks of enalapril treatment to about 50% of pre-treatment values, with no changes after adding salicylate. Plasma angiotensin II concentration fell from 69-6 (53-2) pmol/l to 30-5 (15-1) pmol/l after four weeks and to 29-2 (19-5) pmol/l after eight weeks. Plasma noradrenaline concentration fell from 4-91 (3-22) nmol/l to 2-57 (1-90) nmol/l after four weeks and to 2-05 (0-62) nmol/l after eight weeks.

Creatinine clearance during the night, which was not affected by the converting enzyme inhibitor during the short term study, was also not changed significantly during the extended study. Although salt secretion and free water production were increased during the first two days of enalapril treatment, they returned to their pretreatment values after four and eight weeks, which suggests that converting enzyme inhibitor treatment led to a transient negative salt and water balance.

The night time excretion of dinor-6-keto-prostaglandin F₁₂₅₀, which was not significantly influenced by enalapril during the short term study, dropped significantly from 12-0 (6-2) ng/h to 8-7 (4-0) ng/h after four weeks of taking enalapril and placebo and to 7-4 (4-7) ng/h after another four weeks of taking enalapril and salicylate (figure 4). Corresponding values for dinor-thromboxane B₂ were 15-9 (11-2) ng/h initially, and 9-7 (7-7) ng/h after four weeks. There was no additional fall after four weeks of taking enalapril and salicylate, night time excretion remaining at 9-1 (7-9) ng/h.

The metabolites of renal prostaglandins behaved in the same way (figure 4). There was no significant effect on night time excretion during the short term study, but 6-keto-prostaglandin F₁₂₅₀ excretion fell significantly from 8-4 (4-0) ng/h to 4-9 (2-3) ng/h after four weeks of enalapril alone and to 5-0 (3-7) ng/h after four weeks of enalapril combined with salicylate. Thromboxane B₂ excretion overnight fell from 4-2 (2-4) ng/h initially to 3-5 (1-7) ng/h after four weeks; it also showed no additional decrease when salicylate was added, remaining at 3-3 (2-6) ng/h.

Treatment with enalapril reduced cardiac mass index from 135-1 (46-2) g/m² initially to 130-1 (46-2) after four weeks (NS) and 120-1 (53-6) g/m² after eight weeks (P < 0.05). The end diastolic volume index of the left ventricle was 102-8 (28-3) ml/m² at baseline, 99-6 (27-4) ml/m² after four weeks, and 101-8 (28-3) ml/m² after eight weeks (NS). Ejection fraction improved slightly, but not significantly, from 0-26 (0-10) initially to 0-29 (0-10) after four weeks and 0-32 (0-10) after eight weeks. Maximal aerobic capacity increased significantly from 90 (34) W to 126 (62) W after four weeks, remaining unchanged at 127 (62) W after eight weeks. The maximal rate-pressure product increased significantly from 16-8 (3-9) to 21-6 (7-5) x 10⁶ mm Hg/min after four weeks and remained at 22-8 (5-9) x 10⁶ mm Hg/min after eight weeks. Maximal oxygen consumption increased significantly from 14-1 (4-5) ml/min/kg to 19-6 (7-4) ml/min/kg after four weeks, and remaining at exactly the same value after eight weeks.
Combining salicylate and enalapril in patients with coronary artery disease and heart failure

Figure 4 Overnight excretion of prostaglandin metabolites before trial and after four weeks of enalapril and placebo and four weeks of enalapril and salicylate. Vertical lines show SD. Contrary to findings during the short term part of the study, enalapril reduced the night time excretion of all four metabolites, masking the inhibitory effect of salicylate on thromboxane B₂ excretion.

Discussion

All patients included in the study had cardiac failure and were eating a salt restricted diet; most of them used a diuretic. As a result, their renin-angiotensin and sympathetic nervous systems were strongly activated and plasma converting enzyme activity and plasma angiotensin II and noradrenaline concentrations were high. Five hours after the first dose of the converting enzyme inhibitor enalapril their blood pressure and plasma converting enzyme activity had dropped to values close to a new steady state. This was maintained during the extension of the study.

The fall in plasma angiotensin II and noradrenaline concentrations, however, developed much more slowly. After the first dose plasma angiotensin II concentrations decreased slightly in 11 patients and remained unchanged or even increased in nine. We noticed that the fall in blood pressure preceded the fall in blood concentration of angiotensin II and that blood pressures after converting enzyme inhibition did not correlate well with plasma angiotensin II concentrations. We initially hypothesised that the antihypertensive action of converting enzyme inhibitors is due mainly to raised circulating concentrations of vasodilating prostaglandins. It is now recognised that plasma converting enzyme activity does not necessarily reflect activity of the angiotensin I converting ectoenzyme of elements within the vascular wall and deep inside the tissue. Angiotensin II that remains after converting enzyme inhibition depends on the converting enzyme activity expressed locally by tissue cells, the availability of converting enzyme inhibitor locally to inhibit that activity, and other factors such as the presence of a reactively increased concentration of angiotensin I and other proteases that can convert angiotensin I. The blood pressure lowering effect of converting enzyme inhibition is mainly due to a suppression of the production—by vessel wall ectoenzymes—of angiotensin II acting locally on vascular smooth muscle cells. A comparatively high plasma concentration is maintained by escape of angiotensin II from tissue in which converting enzyme activity is incompletely suppressed or in which angiotensin II is produced by other proteases.

To understand the paradoxical finding of a rise in plasma angiotensin II concentration after the first dose of converting enzyme inhibitor while blood pressure is lowered, it seems relevant that patients in whom this occurred had a considerably higher plasma converting enzyme activity after enalapril than had the others; their angiotensin II production was apparently not as effectively suppressed. When enalapril penetrated into the tissues the plasma angiotensin II concentration began to decrease. The mean for the whole group had dropped to 59% of baseline after the second dose of enalapril, although concentrations close to pretreatment values were still found in four patients. After four weeks, however, plasma angiotensin II concentration had diminished in all patients included in the extended study to a mean of 44% of baseline. Particularly when converting enzyme activity is only weakly inhibited, rising concentrations of angiotensin I can be expected to stimulate production of angiotensin II by tissue converting enzyme. This explains why converting enzyme inhibitors given is once daily usually do not succeed in decreasing plasma angiotensin II concentrations for the full 24 hours. The plasma angiotensin II concentrations above baseline after the first dose were apparently not high enough to exert an appreciable effect on blood pressure. A temporary rise in angiotensin II concentration caused by stimulation of tissue converting enzyme by angiotensin I has been shown in isolated human myocardium. As angiotensin II has toxic effects on heart muscle, our findings suggest that converting enzyme inhibition soon after an infarction should be started cautiously when pump function is compromised.
The fall in plasma noradrenaline concentration was slow and concurrent with that of plasma angiotensin II concentration. The noradrenaline in blood has escaped from tissues. In our study its production was probably stimulated by tissue angiotensin II, whose production was transiently stimulated after the first dose. In contrast to that of noradrenaline, the reduction in prostanooid production was not delayed and excretion of metabolites was suppressed immediately to new steady state values; it followed the course of the drop of blood pressure. Prostanoid synthesis may therefore be stimulated by the same angiotensin II derived from vessel walls that contributed to systemic vasoconstriction. Angiotensin II stimulates the liberation of arachidonic acid and subsequent formation of prostanoids in the endothelium. Our findings of a significant fall in the midday excretion of dinor-prostaglandin F_2_0 after a single dose of enalapril in the morning and a slight increase in the ratio of dinor-6-ketoprostaglandin F_2_0 to dinor-thromboxane B_2_ concentration suggest that angiotensin II stimulates prostanooid synthesis—thromboxane A_2_ synthesis more than that of prostaglandin I_2_. At least in our patients, angiotensin II tips the balance of prostanooid synthesis in favour of that of the vasoconstricting and thromboxenic thromboxane A_2_, thereby amplifying its vasoconstricting effect.

Our data agree with those from an earlier study in normal subjects which concluded that converting enzyme inhibitors stimulate synthesis of vasodialatory prostaglandins by inhibiting the breakdown of bradykinin by kininase II. In that study, as in ours, converting enzyme inhibition also did not raise the plasma concentrations of dinor-6-ketoprostaglandin F_2_0, and dinor-thromboxane B_2_, the metabolites of prostaglandin I_2_ and thromboxane A_2_, but only those of the prostanoids, metabolite prostaglandin E_2_—and then only when the renin-angiotensin system was first stimulated by restriction of sodium intake. Similar results were reported in a comparable study carried out in hypertensive subjects eating a salt restricted diet. In this study thromboxane A_2_ and prostaglandin I_2_ synthesis were unaffected, but prostaglandin E_2_ synthesis was increased and could be blocked in nine out of 10 patients by pretreatment with 25 mg indomethacin four times a day, and in four out of eight others by 600 mg aspirin four times a day. In one study in patients with heart failure, captopril induced a slight increase in plasma concentrations not only of prostaglandin E_2_, but also of 6-ketoprostaglandin F_2_0, from the kidney, and this could be blocked by pretreatment with 50 mg indomethacin. A more recent study in hypertensive subjects showed, however, that captopril prevented the rise in renal prostaglandin I_2_ and prostaglandin E_2_ metabolite excretion that was induced by stimulating the renin-angiotensin system with frusemide.

Our results are inconclusive so far as prostaglandin E_2_ is concerned. Data do not exclude a contribution of an enalapril mediated stimulation of prostaglandin E_2_ synthesis to the unloading effect of the converting enzyme inhibitor, as found for captopril, because prostaglandin E_2_ metabolites were not assessed separately. If, however, prostaglandin E_2_ synthesis was indeed stimulated, and if it contributed to the unloading effect of enalapril, it was not suppressed in most patients by the low dose of salicylate we used. Published work shows that stimulation of the synthesis of vasodialatory prostaglandins by a converting enzyme inhibitor, if it exists, is restricted mostly to prostaglandin E_2_ and that it is not observed in all patients.

The effect of enalapril on the excretion of renal prostanooids in our study was similar to that found for systemic prostanooids, except that at baseline, contrary to what was found for the systemic prostanooids, excretion of 6-ketoprostaglandin F_2_0, was much higher than that of thromboxane B_2_. This probably reflects the highly activated state of the renin-angiotensin system. The mechanism is a specific stimulation of renal prostaglandin I_2_ synthesis by angiotensin II or angiotensin (1-7) or both. Renal prostaglandin I_2_ synthesis has been described as a safety mechanism that protects the renal circulation from excessive vasoconstriction by angiotensin II. We found that this mechanism was indeed active in patients with heart failure. Renal prostaglandin I_2_ synthesis was strongly stimulated and renal thromboxane A_2_ production mildly stimulated by angiotensin II, since after enalapril the excretion of renal thromboxane metabolites was also reduced. The fact that blood pressure fell simultaneously excluded an important contribution of renal prostaglandin I_2_ synthesis to the unloading effect of the converting enzyme inhibitor. Data indicate that the stimulation of prostaglandin I_2_ synthesis is mainly due to angiotensin II as the concentration of angiotensin (1-7), which is derived from angiotensin I, would be expected to increase when conversion of angiotensin I to angiotensin II is blocked by a converting enzyme inhibitor. If stimulation by angiotensin (1-7) were important prostaglandin I_2_ synthesis would have increased after enalapril.

In our study salicylate inhibited the synthesis of systemic and renal thromboxane A_2_ and had no significant effect on prostaglandin I_2_ synthesis. As a result, the ratio of prostaglandin I_2_ to thromboxane A_2_ concentration increased. Selective inhibition of the synthesis of thromboxenic thromboxane A_2_ is considered to be the mechanism underlying the protective effect of salicylate in patients with coronary artery disease. However, the effect of salicylate on thromboxane B_2_ excretion was present only during the first night, after the enalapril effect had waned; daytime excretion of thromboxane B_2_ and dinor-thromboxane B_2_ was not reduced. The apparent absence of effect during the day might be due to pharmacokinetic properties of the salicylate that make the effect trail behind that of enalapril. It is more likely that the effective suppression of thromboxane B_2_ and
Combining salicylate and enalapril in patients with coronary artery disease and heart failure

dinorthromboxane B₂ excretion during the day by enalapril leaves no opportunity for the salicylate to reduce their excretion further. In the extended study the effect of enalapril lasted for the full 24 hours because the drug accumulated. As a result, enalapril mediated suppression of prostanooid excretion had lasted into the night so suppression of overnight thromboxane B₂ excretion by salicylate could no longer be detected. This is in agreement with the conclusion given above that suppression of thromboxane B₂ excretion by enalapril masks suppression by salicylate.

The same happened with blood pressure and ventricular unloading. During the short term study a significant "de-unloading" effect of salicylate addition was found during the night, when the enalapril effect had waned, but during the day no effect was found on average for the whole group. A significant contribution of enalapril induced prostaglandin E₂ synthesis to the blood pressure reduction during the daytime may have been present in at least a few patients, because unloading was completely reversed in three patients, while in the long term study one of the 12 patients showed such a de-unloading effect. Among the others there were a few in which the unloading was partly but not significantly attenuated. De-unloading, if present, had no appreciable effect on improvement of exercise tolerance or on regression of cardiac mass.

The interaction of enalapril and salicylate seems to be far more complicated than originally thought. We found no evidence in favour of an important de-unloading effect of salicylate. If present, the effect was mild and on average not significant. It did not interfere appreciably with reversal of remodelling of the ventricle or with improvement of exercise tolerance. Significant de-unloading is to be expected only in patients in whom the prostaglandin E₂ synthesis is significantly stimulated by the converting enzyme inhibitor. Like other bradykinin mediated effects such as coughing, this seems to occur only in a minority of the patients. Moreover, published data suggest that even if the prostaglandin E₂ synthesis is stimulated by the converting enzyme inhibitor it will probably not be suppressed by low doses of salicylate. The chances that addition of salicylate will significantly reduce the benefit of a converting enzyme inhibitor in patients with heart failure are therefore low.

Surprisingly, evidence was found suggesting that the beneficial effect of salicylate on platelet aggregation through inhibition of the thromboxane A₂ synthesis is shared by the converting enzyme inhibitor. In the studies of left ventricular dysfunction (SOLVD) enalapril reduced mortality in patients with heart failure not only because it delayed progression of heart failure but also, unexpectedly, because it reduced the incidence of reinfarctions by about 20%. The mechanism of the reduction in risk of reinfarction was not clear. Risk was not reduced in patients treated with salicylate. Our results suggest that converting enzyme inhibitors largely reduce the rate of reinfarction by blocking the synthesis of thromboxane A₂ mediated by angiotensin II in patients with a highly activated renin-angiotensin system. This implies that for patients with heart failure the addition of salicylate to enalapril, though not harmful, is probably not very beneficial either.

We thank Dr F Boomsma from the Department of Internal Medicine II of the University Hospital Rotterdam for the rapid determination of angiotensin II concentration. Mr H van der Veen from the Department of Pulmonology of the University Hospital of Leiden for her help with the exercise test and the determination of angiotensin converting enzyme activity; and Mr A van Leeuwen from the Department of Obstetrics of the University Hospital of Leiden for determining urinary prostanooid concentrations. We acknowledge Merck Sharp and Dohme for financial support.


SHORT CASES IN CARDIOLOGY

Leiomyosarcoma in the right atrium and occluding the inferior vena cava

Peter Wilmshurst

The radiographic image (figure) shows a tumour the size and shape of an hen’s egg in the right atrium, outlined by contrast injection in the superior vena cava, that was found in a 50 year old woman who presented with fatigue, jaundice, oedema, and ascites. Venous distension was apparent, particularly in the lower half of the body. She was in sinus rhythm with a normal cardiac impulse and no murmurs. The liver was enlarged but not pulsatile. Ultrasound examination of the abdomen showed a tumour at the hilum of the liver with total obstruction of the inferior vena cava. Venography confirmed the obstruction with contrast draining to the right atrium via the azygos system.

A biopsy specimen of the right atrial tumour was taken via the right internal jugular vein using a Cordis biopome (7 French gauge). During biopsy the tumour felt much harder than normal cardiac tissue. Histological examination showed that the tumour was a leiomyosarcoma. It was thought to have invaded the right atrium rather than have originated there. Despite treatment the patient died within six months of presentation.

Masses in the right atrium may be thrombus (arising in situ or embolic), rarer types of emboli, massive vegetations (especially in fungal endocarditis), or tumours. The commonest variety of cardiac tumour is a benign myxoma. In this case, the ultrasound scan suggested that the mass was a malignant tumour invading the right atrium from the inferior vena cava. A histological diagnosis was considered necessary to confirm the diagnosis of malignancy (because some benign tumours, such as leiomyomatosis, can grow into the right atrium from the inferior vena cava) and to determine what treatment was appropriate. In this case the tumour was a relatively rare solid tumour, a leiomyosarcoma arising in the vena cava. There are about 20 reported cases. Other malignant tumours that can invade the atrium from the lumen of the vena cava include renal adenocarcinomas and hepatomas. Before surgical removal of a right atrial mass is attempted, it is advisable to visualise the vena cava by ultrasound or contrast radiography to exclude such invasion.